Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haplo PTCy for Sickle Cell Disease or ß-Thalassemia
NCT05736419Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2023
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies, Modified Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of fludarabine, dexamethasone, cyclophosphamide, bortezomib, rituximab in sickle cell disease (SCD), beta thalassemia, sponsored by Memorial Sloan Kettering Cancer Center. Started Feb 2023; status: recruiting.
02
Drugs
fludarabinedexamethasonecyclophosphamidebortezomibrituximab
03
Conditions
sickle cell disease (SCD)beta thalassemia
Beyond the preview
Go deeper on NCT05736419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05736419.